Sign In
Last checked at 
18 Sep 2024 13:20
Issued: 18 September 2024, London UK
Statement: Zantac (ranitidine) litigation - Russell and Hughes cases
GSK plc (LSE/NYSE: GSK) today confirmed it has reached two confidential settlements in cases filed in California State Court with Mr. John Russell, resolving his bladder cancer case, and with Ms. Annette Hughes, resolving her colorectal case. GSK does not admit any liability in either settlement. The cases will now be dismissed as to GSK.
Since 2019, following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
GSK enquiries | |||
Media: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
Dan Smith | +44 (0) 20 8047 5502 | (London) | |
Kathleen Quinn | +1 202 603 5003 | (Washington DC) | |
Lyndsay Meyer | +1 202 302 4595 | (Washington DC) | |
| |||
Investor Relations: | Nick Stone | +44 (0) 7717 618834 | (London) |
James Dodwell | +44 (0) 20 8047 2406 | (London) | |
Mick Readey | +44 (0) 7990 339653 | (London) | |
Josh Williams | +44 (0) 7385 415719 | (London) | |
Camilla Campbell | +44 (0) 7803 050238 | (London) | |
Steph Mountifield | +44 (0) 7796 707505 | (London) | |
Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) | |
Frannie DeFranco | +1 215 751 4855 | (Philadelphia) |
Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q2 Results for 2024.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
Follow the stocks
